Celldex Therapeutics Inc:
* CELLDEX PROVIDES CORPORATE UPDATE AND REPORTS FOURTH QUARTER AND YEAR END 2019 RESULTS
* Q4 LOSS PER SHARE $0.64
* Q4 REVENUE $900,000 VERSUS $9.5 MILLION
* CELLDEX THERAPEUTICS - BELIEVES CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES AT DEC 31, 2019 SUFFICIENT TO FUND PLANNED OPERATIONS INTO Q1 2021 Source text for Eikon: Further company coverage:
Our Standards: The Thomson Reuters Trust Principles.